Here’s a roundup of the latest dealflow and investment news:
- Ocular Therapeutix completes Series D financing to support Phase II sustained drug delivery clinical trials
Ocular Therapeutix Inc. closed a $14 million Series D round of financing. The round was led by Ascension Health Ventures of St. Louis, Missouri, with continued participation by existing investors including Polaris Ventures, SV Life Sciences and Versant Ventures. The funding will be used to support Ocular Therapeutix’s Phase II clinical trials across a variety of therapeutic areas. The first trial will be conducted to reinforce safety and test efficacy of their first sustained drug delivery system, a moxifloxacin-loaded punctum plug. Following, Ocular Therapeutix plans to initiate additional Phase II clinical trials for punctum plugs designed for the management of glaucoma, dry eye, and allergies.
- Massive Health drums up $2.25 million
San Francisco-based Massive Health announced a $2.25 million round with Mohr Davidow, Andreessen Horowitz, Charles River Ventures, Felicis VC, the Collaborative Fund and Greylock Partners, according to PE Hub. Several angels also are in the deal. The company is designing a mobile app to manage disease by using social graphs and social networks and help people stay well.
- Seattle Genetics announces exercise of over-allotment option
Seattle Genetics Inc. (NSDQ:SGEN) announced that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase an additional 1,500,000 shares of common stock. Gross proceeds from the offering of an aggregate of 11,500,000 shares at a price to the public of $15.50 per share, before underwriting discounts and commissions and other offering expenses, will be approximately $178 million. The offering is expected to close on February 7, 2011, subject to customary closing conditions.
- VertiFlex announces financing and new investment partner
VertiFlex Inc., a percutaneous and motion preserving spinal surgery technologies company, completed of a $14 million equity placement, with provision for an additional $14 million investment within twelve months. Current investors Aberdare Ventures, Alta Partners and New Enterprise Associates were joined in the financing by new investor Thomas, McNerney & Partners. The new capital will be used to complete enrollment in the Superion Interspinous Spacer (ISS) IDE Trial before the end of 2011, and to advance global market development of the technology.
- Spine Wave drums up $17.5 million
Shelton, Conn.-based Spine Wave Inc. raised $17.5 million in a funding round led by former investor New Enterprise Associates. Morgenthaler Ventures, Compass Global Fund, New Leaf Venture Partners, Canaan Partners, Foundation Medical Partners and Memphis Implant Partners also backed the round. The company plans use the funding to grow its commercial operations and help bring its NuCore Injectable Nucleus to clinical trials.